Live Chat ×
Skip to main content

Impact of 2018 Updated ASCO/CAP Guidelines on HER2 in Situ Hybridization (ISH) Testing

This item is expired.

From the 2019 Joint Annual Meeting (June 26, 2019)
Presented by Katherine Geiersbach, M.D., FCAP
This presentation will describe the changes in the interpretation of in situ hybridization (ISH) testing under the updated ASCO/CAP Guidelines for HER2 testing in breast cancer published in 2018.

At the conclusion of this presentation, participants will be able to:

  1. Describe the importance of HER2 testing in breast cancer
  2. Define and interpret 5 groups of in situ hybridization (ISH) results in breast cancer
  3. Discuss primary and reflex ISH testing on 3 groups of ISH results, including the distribution of positive and negative results based on the combined interpretation of immunohistochemistry and ISH

This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area General (QA, Molecular) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.